JP2016529284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529284A5 JP2016529284A5 JP2016537829A JP2016537829A JP2016529284A5 JP 2016529284 A5 JP2016529284 A5 JP 2016529284A5 JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016529284 A5 JP2016529284 A5 JP 2016529284A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- formulation
- parp inhibitor
- cholesterol
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 claims 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 19
- 238000009472 formulation Methods 0.000 claims 17
- 239000012661 PARP inhibitor Substances 0.000 claims 15
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 15
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 10
- 235000012000 cholesterol Nutrition 0.000 claims 10
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 9
- 239000002105 nanoparticle Substances 0.000 claims 8
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 4
- 229960000572 olaparib Drugs 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- AHIVQGOUBLVTCB-AWEZNQCLSA-N 2-[2-fluoro-4-[(2s)-pyrrolidin-2-yl]phenyl]-1h-benzimidazole-4-carboxamide Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C(C(=C1)F)=CC=C1[C@@H]1CCCN1 AHIVQGOUBLVTCB-AWEZNQCLSA-N 0.000 claims 1
- QIHBWVVVRYYYRO-ZDUSSCGKSA-N 3-(4-oxo-1h-quinazolin-2-yl)-n-[(1s)-1-phenylethyl]propanamide Chemical compound C1([C@@H](NC(=O)CCC=2NC(=O)C3=CC=CC=C3N=2)C)=CC=CC=C1 QIHBWVVVRYYYRO-ZDUSSCGKSA-N 0.000 claims 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims 1
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 claims 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 1
- JJWMRRNGWSITSQ-UHFFFAOYSA-N 5-phenacyloxy-2h-isoquinolin-1-one Chemical compound C=1C=CC(C(NC=C2)=O)=C2C=1OCC(=O)C1=CC=CC=C1 JJWMRRNGWSITSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012827 ATM inhibitor Substances 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- SEKJSSBJKFLZIT-UHFFFAOYSA-N LSM-1988 Chemical compound C1=CC(CN(C)C)=CC=C1C1=NC2=CC=CC3=C2N1CCNC3=O SEKJSSBJKFLZIT-UHFFFAOYSA-N 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- RURAZZMDMNRXMI-UHFFFAOYSA-N PJ34 hydrochloride Chemical compound Cl.C1=CC=C2C3=CC(NC(=O)CN(C)C)=CC=C3NC(=O)C2=C1 RURAZZMDMNRXMI-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 cationic lipid Chemical class 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 230000000887 hydrating effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229950002133 iniparib Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361870258P | 2013-08-27 | 2013-08-27 | |
| US61/870,258 | 2013-08-27 | ||
| PCT/US2014/053006 WO2015031536A1 (en) | 2013-08-27 | 2014-08-27 | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016529284A JP2016529284A (ja) | 2016-09-23 |
| JP2016529284A5 true JP2016529284A5 (enExample) | 2017-10-05 |
Family
ID=52587308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537829A Pending JP2016529284A (ja) | 2013-08-27 | 2014-08-27 | ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10111871B2 (enExample) |
| EP (1) | EP3038600B1 (enExample) |
| JP (1) | JP2016529284A (enExample) |
| WO (1) | WO2015031536A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PT3313443T (pt) * | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| BR112018002941B1 (pt) | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
| BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| WO2017136330A1 (en) * | 2016-02-01 | 2017-08-10 | Abbvie Inc. | Extended release formulations of veliparib for the treatment of cancer |
| GB201608885D0 (en) * | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
| CN107951861B (zh) * | 2016-10-17 | 2020-12-01 | 南京绿叶制药有限公司 | 一种脂质纳米粒膜材料组合物 |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| CN108201536A (zh) | 2016-12-16 | 2018-06-26 | 中国科学院上海药物研究所 | 一种奥拉帕尼口服缓控释药物组合物及其用途 |
| CN108201535A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种维利帕尼缓控释药物组合物及其用途 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| US11737977B2 (en) * | 2017-04-12 | 2023-08-29 | Beijing Inno Medicine Co., Ltd. | Cerasome delivery system for targeting activated CD44 molecule, preparation method and use thereof |
| US20210030680A1 (en) * | 2018-04-13 | 2021-02-04 | The Board Of Regents Of University Of Texas System | Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer |
| KR102017115B1 (ko) * | 2018-05-15 | 2019-09-02 | 충남대학교산학협력단 | 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| BR112021025105A2 (pt) * | 2019-06-12 | 2022-03-15 | Reven Ip Holdco Llc | Métodos e composições para melhorar os resultados de pacientes com câncer |
| US11648211B2 (en) * | 2019-09-23 | 2023-05-16 | Northeastern University | Nanoencapsulated combination drug formulations |
| CN111187416A (zh) * | 2020-01-17 | 2020-05-22 | 广州古泉生物科技有限公司 | 一种壳聚糖-g-聚ε-己内酯衍生物载药纳米胶束的制备方法和应用 |
| WO2022115207A1 (en) * | 2020-11-25 | 2022-06-02 | Trustees Of Dartmouth College | Method for attenuating neuroinflammation |
| PL438742A1 (pl) * | 2021-08-14 | 2023-02-20 | Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością | Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną |
| JP2024543323A (ja) * | 2021-11-10 | 2024-11-21 | クリチテック，インコーポレイテッド | ルカパリブ粒子およびその使用 |
| US20250223571A1 (en) | 2022-03-30 | 2025-07-10 | Bioneedle Drug Delivery B.V. | A process for storing biologically active constructs in a biodegradable material |
| CN116297044A (zh) * | 2022-12-07 | 2023-06-23 | 浙江萃泽医药科技有限公司 | 一种糠酸莫米松鼻喷雾剂中微晶纤维素粒径的测试方法 |
| WO2025024581A1 (en) * | 2023-07-24 | 2025-01-30 | University Of Maryland, College Park | Parp-inhibitor nanoparticles and methods thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2058940C (en) | 1989-06-23 | 2000-05-09 | Helen Loughrey | Targeted liposomes and methods for liposome-protein coupling |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NL9000207A (enExample) | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| JP2001026544A (ja) | 1999-05-11 | 2001-01-30 | Sankyo Co Ltd | 脂溶性抗腫瘍薬のリポソーム製剤 |
| US7037520B2 (en) * | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| US20090220587A1 (en) | 2005-02-01 | 2009-09-03 | United State Army | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands |
| BRPI0717800A2 (pt) * | 2006-10-06 | 2014-09-09 | Politechnic Inst Univ New York | COMPOSIÇÃO DE LIPOSSOMAS SENSÍVEIS AO pH |
| EP2118127A4 (en) | 2007-01-31 | 2010-12-01 | Affymax Inc | NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES |
| US20100129456A1 (en) * | 2007-05-14 | 2010-05-27 | Ltt Bio-Pharma Co., Ltd. | Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group |
| KR100979462B1 (ko) | 2007-08-03 | 2010-09-02 | 한국화학연구원 | 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법 |
| US20110233079A1 (en) * | 2009-06-30 | 2011-09-29 | Macinnes Susan E | Medical Kit, Packaging System, Instruction Insert, and Associated Methods |
| TWI468188B (zh) | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
| WO2009129387A2 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| US20100104629A1 (en) * | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
| US20110123451A1 (en) | 2009-11-21 | 2011-05-26 | Max Kullberg | Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin |
| MX340319B (es) | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| WO2012031205A2 (en) | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
-
2014
- 2014-08-27 WO PCT/US2014/053006 patent/WO2015031536A1/en not_active Ceased
- 2014-08-27 EP EP14841089.7A patent/EP3038600B1/en active Active
- 2014-08-27 JP JP2016537829A patent/JP2016529284A/ja active Pending
- 2014-08-27 US US14/914,932 patent/US10111871B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529284A5 (enExample) | ||
| Masjedi et al. | An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications | |
| Hao et al. | Supramolecular chemotherapy: carboxylated pillar [6] arene for decreasing cytotoxicity of oxaliplatin to normal cells and improving its anticancer bioactivity against colorectal cancer | |
| Pereira et al. | Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity | |
| Li et al. | Self-assembled nanoparticles based on amphiphilic anticancer drug–phospholipid complex for targeted drug delivery and intracellular dual-controlled release | |
| Tawfik et al. | Low-frequency versus high-frequency ultrasound-mediated transdermal delivery of agomelatine-loaded invasomes: development, optimization and in-vivo pharmacokinetic assessment | |
| ES2762224T3 (es) | Liposomas que comprenden lípidos conjugados con polímero y usos relacionados | |
| CN108024960B (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| JP2019501198A5 (enExample) | ||
| JP2014532665A5 (enExample) | ||
| JP2015519330A5 (enExample) | ||
| CN109350600B (zh) | 设计脂质体水相和非水相部分的组成来控制药物的释放趋势 | |
| JP2015523355A5 (enExample) | ||
| Duong et al. | One step encapsulation of small molecule drugs in liposomes via electrospray-remote loading | |
| Gandhi et al. | Lipid-Based inhalable micro-and nanocarriers of active agents for treating non-small-cell lung cancer | |
| Ma et al. | Cancer cell targeting, controlled drug release and intracellular fate of biomimetic membrane-encapsulated drug-loaded nano-graphene oxide nanohybrids | |
| JP2015530382A5 (enExample) | ||
| EP1393719A1 (en) | Camptothecin-carboxylate formulations | |
| Maddiboyina et al. | Perspectives on cutting‐edge nanoparticulate drug delivery technologies based on lipids and their applications | |
| Xu et al. | Lipid-coated CaCO3 nanoparticles as a versatile ph-responsive drug delivery platform to enable combined chemotherapy of breast cancer | |
| KR20210081256A (ko) | 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트 | |
| Nayak et al. | Applications of nanovesicular drug delivery | |
| Mozafari et al. | An overview of liposome-derived nanocarrier technologies | |
| Hu et al. | Liposomes in drug delivery: status and advances | |
| JP2018527335A5 (enExample) |